HALEOS LABS profit and loss

Latest FY26

Revenue: ₹334cr−3.2% on FY25
EBITDA: ₹44.7cr−0.8% on FY25
Net profit: ₹17.8cr−5.0% on FY25
EPS: ₹57.26−13.9% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	324	334	345	306	316	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	3.1	2.4	4.9	3.8	3.1
	327	336	350	310	319
	161	147	150	150	171
	−13.7	0.0	0.0	0.0	0.0
	−14.9	−8.2	4.2	1.0	0.1
	66.6	65.4	59.5	49.3	43.4
	6.5	6.4	8.7	10.2	6.8
	15.9	15.5	15.0	14.9	10.8
	84.7	85.2	86.1	74.4	72.0
	306	311	323	300	304
	40.9	44.7	45.0	31.1	28.8
	25.0	29.2	30.0	16.2	18.0
Profit
	21.6	25.2	26.2	9.8	14.2
	0.0	0.0	0.0	0.0	2.4
	21.6	25.2	26.2	9.8	16.6
	4.6	5.5	9.0	4.1	3.5
	1.8	1.9	−1.5	−0.5	1.7
	6.4	7.4	7.5	3.5	5.2
	15.3	17.8	18.7	6.3	11.4
	15.3	17.8	18.7	6.3	11.4
	0.2	0.1	0.1	−0.5	0.0
	15.4	17.9	18.9	5.9	11.4
	15.8	17.3	20.1	9.1	11.5
	−0.5	0.5	−1.4	−2.8	−0.1
Per share
	₹52.27	₹57.26	₹66.51	₹30.08	₹37.92
	₹52.27	₹57.26	₹66.51	₹30.08	₹37.92
Other comprehensive income — detail
	0.2	0.1	0.1	—	—
	−0.2	−0.2	−0.2	—	—
	—	—	—	0.6	−0.0
	0.1	0.0	0.0	—	—
	—	—	—	−0.2	0.0
	15.9	17.4	20.2	8.7	11.5
	−0.5	0.5	−1.3	−2.9	−0.1
Per share — as-filed variants
	₹52.27	₹57.26	₹66.51	₹30.08	₹37.92
	₹52.27	₹57.26	₹66.51	₹30.08	₹37.92
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	192	195	191	155	144
	59.3%	58.5%	55.3%	50.6%	45.7%
Adjusted (ex-exceptional items) — derived
	21.6	25.2	26.2	9.8	14.2
	0.0	0.0	0.0	0.0	2.4
	15.3	17.8	18.7	6.3	9.8
	₹52.27	₹57.26	₹66.51	₹30.08	₹32.55

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

HALEOSLABS₹1,450.60

HALEOS LABS LIMITED

· Pharma & Health

Annual Quarterly₹ CrorePeersALBERTDAVD VALIANTLAB MEDICO MEDICAMEQ ZIMLAB AAREYDRUGS NECLIFE ANUHPHRMcap ₹439 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	315.6	306.0	344.7	333.8	324.2
Other Income	3.1	3.8	4.9	2.4	3.1
Total Income	318.6	309.8	349.6	336.2	327.3
Expenses
+ Cost of Materials Consumed	171.3	150.2	149.9	146.7	160.6
+ Purchases of Stock-in-Trade	0.0	0.0	0.0	0.0	-13.7
+ Changes in Inventories	0.1	1.0	4.2	-8.2	-14.9
+ Employee Benefit Expense	43.4	49.3	59.5	65.4	66.6
+ Finance Costs	6.8	10.2	8.7	6.4	6.5
+ Depreciation & Amortisation	10.8	14.9	15.0	15.5	15.9
+ Other Expenses	72.0	74.4	86.1	85.2	84.7
Total Expenses	304.4	299.9	323.4	311.0	305.7
EBITDA	28.8	31.1	45.0	44.7	40.9
EBIT	18.0	16.2	30.0	29.2	25.0
Profit
PBT before Exceptional Items	14.2	9.8	26.2	25.2	21.6
+ Exceptional Items	2.4	0.0	0.0	0.0	0.0
Pretax Income	16.6	9.8	26.2	25.2	21.6
+ Current Tax	3.5	4.1	9.0	5.5	4.6
+ Deferred Tax	1.7	-0.5	-1.5	1.9	1.8
Tax Expense	5.2	3.5	7.5	7.4	6.4
Net Income	11.4	6.3	18.7	17.8	15.3
+ Net Income — Continuing Ops	11.4	6.3	18.7	17.8	15.3
+ Other Comprehensive Income	0.0	-0.5	0.1	0.1	0.2
Total Comprehensive Income	11.4	5.9	18.9	17.9	15.4
Net Income to Common	11.5	9.1	20.1	17.3	15.8
Minority Interest	-0.1	-2.8	-1.4	0.5	-0.5
Per Share
Basic EPS	37.92	30.08	66.51	57.26	52.27
Diluted EPS	37.92	30.08	66.51	57.26	52.27
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	0.1	0.1	0.2
+ Tax on Items NOT to be Reclassified	—	—	-0.2	-0.2	-0.2
+ Tax on Items NOT to be Reclassified — alt tag	-0.0	0.6	—	—	—
+ Tax on Items to be Reclassified	—	—	0.0	0.0	0.1
+ Tax on Items to be Reclassified — alt tag	0.0	-0.2	—	—	—
Comprehensive Income — Owners of Parent	11.5	8.7	20.2	17.4	15.9
Comprehensive Income — Non-controlling Interests	-0.1	-2.9	-1.3	0.5	-0.5
Per Share — as-filed variants
Basic EPS — Continuing Operations	37.92	30.08	66.51	57.26	52.27
Diluted EPS — Continuing Operations	37.92	30.08	66.51	57.26	52.27
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	144.2	154.8	190.7	195.3	192.3
Gross Margin %	45.68	50.59	55.31	58.50	59.30
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	14.2	9.8	26.2	25.2	21.6
− Exceptional Items (reconciliation)	2.4	0.0	0.0	0.0	0.0
Net Income Adj (tax-effected)	9.8	6.3	18.7	17.8	15.3
EPS Adj	32.55	30.08	66.51	57.26	52.27
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	3.0	3.0	3.0	3.0	3.0

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.